Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer’s disease
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Amyloid-β (Aβ) accumulation in the brain is a pivotal event in the pathogenesis of Alzheimer's disease (AD), and its clearance from the brain is impaired in sporadic AD. Previous studies suggest that approximately half of the Aβ produced in the brain is cleared by transport into the periphery. However, the mechanism and pathophysiological significance of peripheral Aβ clearance remain largely unknown. The kidney is thought to be responsible for Aβ clearance, but direct evidence is lacking. In this study, we investigated the impact of unilateral nephrectomy on the dynamic changes in Aβ in the blood and brain in both humans and animals and on behavioural deficits and AD pathologies in animals. Furthermore, the therapeutic effects of the diuretic furosemide on Aβ clearance via the kidney were assessed. We detected Aβ in the kidneys and urine of both humans and animals and found that the Aβ level in the blood of the renal artery was higher than that in the blood of the renal vein. Unilateral nephrectomy increased brain Aβ deposition; aggravated AD pathologies, including Tau hyperphosphorylation, glial activation, neuroinflammation, and neuronal loss; and aggravated cognitive deficits in APP/PS1 mice. In addition, chronic furosemide treatment reduced blood and brain Aβ levels and attenuated AD pathologies and cognitive deficits in APP/PS1 mice. Our findings demonstrate that the kidney physiologically clears Aβ from the blood, suggesting that facilitation of Aβ clearance via the kidney represents a novel potential therapeutic approach for AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with CKD and animals undergoing unilateral nephrectomy exhibit elevated levels of circulating and cerebral Aβ, along with impaired cognition.254–256”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [255]
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“It has been proposed that abnormal Aβ accumulation in the brain plays a pivotal role in disease pathogenesis and causes neurodegeneration, neuroinflammation, impaired neuronal function, and ultimately cognitive decline in AD [3, 4].”
Background2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678 · cited 5×
“Clearance of Aβ from the brain is a major therapeutic strategy for AD [7].”
InfluentialPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · cited 1×
“Given that kidney function declines with age and that kidney dysfunction is prevalent in elderly people with high levels of amyloidosis [28], it is probable that dysfunction of Aβ clearance via the kidney may participate in the pathogenesis of AD [8, 22].”
BackgroundA critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Self-citationThe Klotho proteins in health and disease
Kuro-o, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0078-3 · Cited by 707 · cited 1×
“kidney in the periphery [27], were not changed after unilateral nephrectomy.”
BackgroundDeane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 548
Nielsen, R., Christensen, E. I., & Birn, H. (2016) · Kidney International · doi:10.1016/j.kint.2015.11.007 · Cited by 486 · cited 1×
“Previous studies suggested that protein uptake in the renal tubule is mainly mediated by two receptors, megalin and cubilin, which are expressed in renal tubular epithelial cells [20].”
Background
Cited by
Feng, S., Wu, C., Zou, P., Deng, Q., Chen, Z., Li, M., Zhu, L., Li, F., Liu, T. C.-Y., Duan, R., et al. (2023) · Theranostics · doi:10.7150/thno.81951 · Cited by 164
“Our findings are consistent with a previous study, wherein they demonstrated that physiological clearance of Aβ by the kidney was involved in the development of AD pathogenesis [53].”
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Self-citationPhysiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02559-z · Cited by 110
Self-citationPropagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease
Yuan, X., Nie, S., Yang, Y., Liu, C., Xia, D., Meng, L., Xia, Y., Su, H., Zhang, C., Bu, L., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-024-01866-2 · Cited by 92
“RF is associated with impaired clearance or metabolism of a variety of substances, leading to neurotoxicity and cognitive impairment 28,29 .”
Wu, Y., Dong, J.-H., Dai, Y.-F., Zhu, M.-Z., Wang, M.-Y., Zhang, Y., Pan, Y.-D., Yuan, X.-R., Guo, Z.-X., Wang, C.-X., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.06.002 · Cited by 84
Metadata
- Authors
- Tian, D.-Y., Cheng, Y., Zhuang, Z.-Q., He, C.-Y., Pan, Q.-G., Tang, M.-Z., Hu, X.-L., Shen, Y.-Y., Wang, Y.-R., Chen, S.-H., Sun, H.-L., Sun, P.-Y., Yu, Z.-Y., Fan, D.-Y., Bu, X.-L., Tan, C.-R., Zeng, G.-H., Wang, J., Zhao, H.-W., & Wang, Y.-J.
- Affiliations
- Army Medical University (CN)
- Corresponding author
- Wang, Ye-Ran
- Wang, Jun
- Wang, Yan-Jiang
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-04-08
- Volume
- 26
- Issue
- 10
- Pages
- 6074-6082
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W3141671875
- Cited by
- 100
- References
- 37
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 26 · 2023: 23 · 2022: 11 · 2021: 4
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81930028, 81625007, 31921003, 91749206)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- amyloid-beta clearance, kidney, Alzheimer's disease, unilateral nephrectomy, furosemide, diuretics, APP/PS1 mice, tau hyperphosphorylation, neuroinflammation, glial activation, cognitive impairment, blood-brain barrier
- MeSH terms
- Alzheimer Disease, Animals, Brain, Disease Models, Animal, Kidney, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41380-021-01073-6
- The paper
- Tian, D.-Y., Cheng, Y., Zhuang, Z.-Q., He, C.-Y., Pan, Q.-G., Tang, M.-Z., Hu, X.-L., Shen, Y.-Y., Wang, Y.-R., Chen, S.-H., Sun, H.-L., Sun, P.-Y., Yu, Z.-Y., Fan, D.-Y., Bu, X.-L., Tan, C.-R., Zeng, G.-H., Wang, J., Zhao, H.-W., & Wang, Y.-J. (2021). Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer’s disease. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01073-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.